Fulcrum Therapeutics' Q3 net loss narrows

Fulcrum Therapeutics

29/10/2025 11:23

Overview

Fulcrum Q3 net loss narrows to $19.6 mln from $21.7 mln last year

Operating income for Q3 missed analyst expectations

Fulcrum ended Q3 with $200.6 mln in cash, runway into 2028

Outlook

Fulcrum expects to release 20 mg dose cohort data by year-end 2025

Company plans to present additional clinical data at ASH Congress in December 2025

Fulcrum anticipates cash runway to fund operations into 2028

Result Drivers

PIONEER TRIAL RESULTS - Encouraging results from 12 mg dose cohort in PIONEER trial showed improvements in fetal hemoglobin and markers of hemolysis

20 MG DOSE COHORT - Completed enrollment in 20 mg dose cohort of PIONEER trial, with data expected by year-end

PIPELINE ADVANCEMENT - Plans to submit IND for bone marrow failure syndromes in Q4 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$19.59 mln
Q3 Operating Income
Miss
-$21.86 mln
-$20.60 mln (8 Analysts)
Q3 Basic EPS
-$0.31
Q3 Operating Expenses
$21.85 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Fulcrum Therapeutics Inc is $12.50, about 20% above its October 28 closing price of $10.00

Press Release: ID:nGNX3fcfh6

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)